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Venous thromboembolism (VTE) is categorised as deep venous thrombosis (DVT) and pulmonary embolism (PE). VTE is
associated with high morbidity and causes a huge ﬁnancial burden on patients, hospitals, and governments. Both acquired and
hereditary risks factors contribute to VTE. To diagnose VTE, noninvasive cost-eﬀective diagnostic algorithms including clinical
probability assessment and D-dimer measurement may be employed followup by compression ultrasonography for suspected
DVT patients and multidetector computed tomography angiography for suspected PE patients. There are pharmacological and
mechanical interventions to manage and prevent VTE. The pharmacological approaches mainly target pathways in coagulation
cascade nonspeciﬁcally: conventional anticoagulants or speciﬁcally: new generation of anticoagulants. Excess bleeding is one
of the major risk factors for pharmacological interventions. Hence, nonpharmacological or mechanical approaches such as
inferior vena cava ﬁlters, graduated compression stockings, and intermittent pneumatic compression devices in combination with
pharmacological interventions or alone may be a good approach to manage VTE.
1.Introduction
Venous thromboembolism (VTE) is a major health and
ﬁnancial burden that aﬀects the community [1]. About
30000 Australian hospitalisations may be caused by VTE
that result in losing life of 5000 patients each year [2]. This
condition is the third most common vascular disorder in
Caucasianpopulationsaftermyocardialinfarctionandstroke
[3]. VTE is an acute event which was estimated to complicate
2-3 per 1000 hospital admissions followed by principle diag-
nosis [1]. VTE presents clinically as deep venous thrombosis
(DVT) and pulmonary embolism (PE) with serious out-
comes in both men and women [3]. However, most of these
complications and deaths are preventable with appropriate
administration of cost-eﬀective antithrombotic drugs and
nonpharmacological interventions [2]. There are various
strategies to investigate suspected VTE including clinical
pretest probability combined with/without measurement
of D-dimer, known as algorithm strategies, and imaging
techniques [4]. In this paper we have summarised several
aspects of VTE including diﬀerent classiﬁcations, potential
risk factors, various diagnostic methods, and prevention and
treatment interventions.
2. Classiﬁcations
2.1. Deep Venous Thrombosis (DVT). DVT usually initiates
inthecalfareaoftheleg.Themajorityofthrombiforminthe
deepveinsbelowthepoplitealtrifurcation(distalDVT)most
likely to resolve spontaneously with no symptoms [5, 6].
About 60–70% of patient with symptomatic VTE develop
DVT [7]. Most patients present with symptoms when distal
DVT extend to the popliteal and femoral veins and other
proximal vein [5, 6]. DVT can lead to complications such
as postphlebitic syndrome, PE, and death [4]. There is
a 50% chance that patients with untreated symptomatic
proximal DVT develop symptomatic PE within 3 months2 ISRN Hematology
[5, 6]. An important complication of DVT is postthrombotic
syndromethatdevelopsin20–50%ofpatientsandmayresult
in lifelong limb pain, swelling, heaviness, oedema, and leg
ulcers [8, 9]. DVT reoccurs in about 10% of patients who
may develop severe postthrombotic syndrome within 5 years
[5, 6].
2.2. Pulmonary Embolism (PE). PE symptoms, such as new
or worsening dyspnoea, chest pain, or sustained hypotension
with no alternative cause [10], occur in about 30–40% of
patients with VTE [7, 11] .T h es u r v i v a lr a t ef o rp a t i e n t sw i t h
PE is worse than DVE as the sudden death is the initial
clinical presentation of 25% of these patients [12]. When this
condition is diagnosed in patients, with no further treatment
the fatalityrate can reach 25% [13]. However, prescription of
anticoagulant reduces this risk to 1.5% [14].
3. Risk Factors
Both acquired and hereditary factors play essential roles in
development of VTE [15–17]. The acquired risk factors for
VTE are categorised as strong (odds ratio >10), moderate
(odds ratio 2–9), and weak (odds ratio <2) [15]. Fracture
(hip or leg), hip or knee replacement, major general surgery,
major trauma, and spinal cord injury are considered as
strongriskfactors[15].Moderateriskfactorsincludearthro-
scopic knee surgery, central venous lines, chemotherapy,
congestive heart or respiratory failure, hormone replace-
ment therapy, malignancy, oral contraceptive therapy, par-
alytic stroke, pregnancy/postpartum, previous VTE, and
thrombophilia [15]. Whereas bed rest (>3 days), extended
immobility (air travel >8 hours), increasing age (≥40
years), laparoscopic surgery, obesity, pregnancy/antepartum,
and varicose veins are considered as weak risk factors
[6, 15].
A variety of inherited factors contribute to VTE as
well [15–17]. These are also known as strong, medium
and weak genetic risk factors [17]. Deﬁciencies of some
natural coagulation inhibitors including antithrombin (AT),
protein C (PC), and its cofactor protein S (PS), insuﬃciency
of anticoagulant pathways such as tissue factor pathway
inhibitor (TFPI), thrombomodulin and endothelial protein
Cr e c e p t o r( E P C R )[ 16, 17], and elevated level of factor
VIII [18, 19] belong to strong genetic risk factors. Moderate
genetic risk factors consist of mutation in the factor V
Leiden (FVL) causing resistance to activated protein C
(APC-resistance), a mutation in the 3 -untranslated part of
the prothrombin (Factor II) gene (prothrombin 20210A,
rs 1799963) which results in increased prothrombin lev-
els, blood group (non-O blood group), and a C- to T-
variation at position of 10034 in the ﬁbrinogen gamma
chain (rs 2066865) leading to reduction of the fraction of
gammaﬁbrinogen in plasma [17]. Risk factors, with relative
risk 1.0–1.5, such as mutation in C > T at position 677
(rs1801133) methylenetetrahydrofolate reductase (MTHFR)
resulting in minor elevation of homocysteine levels [17, 20],
and homozygous factor XIII 34Val alleles are categorised as
weak genetic risk factors [21].
Table 1: Clinical characteristics for predicting the pretest probabil-
ityofdeepvenousthrombosis.TheWellsscoremodeldemonstrates




Paralysis or plaster immobilisation +1
Bed rest >3d a y so rm a j o rs u r g e r y<4w e e k s +1
Localised tenderness along the distribution of the deep
venous system
+1
Entire leg swollen +1
Calf swelling >3cm when compared with asymptomatic leg +1
Pitting oedema +1
Collateral superﬁcial veins (nonvaricose) +1
Previously documented deep vein thrombosis +1







The initial diagnostic step for determination of VTE is the
clinical probability assessment [24]. For suspected DVT, the
Wells score has well-established criteria (Table 1)[ 22]. Based
on this clinical model, pre-test probability may predict for
patients with clinical characteristics described in Table 1
[22, 23]. A score ≥2 indicates that the probability of DVT is
l i k e l y ,a n das c o r eo f<2 indicates that the probability of DVT
is unlikely [23]. The Wells score for suspected PE is listed in
Table 2 [24]. A score >4 indicates PE likely, and a score of ≤4
indicates PE unlikely [24]. The limitation of Wells’ scoring
system may be subjective nature of each criterion and its
reliability on the physicians’ judgment [25]. Other scoring
systems to predict PE are revised Geneva and simpliﬁed
revised Geneva (Table 2)[ 24–26]. Revised Geneva score is
based on clinical variable and independent from physicians’
judgement (Table 2)[ 25]. To prevent miscalculations in an
acute setting, simpliﬁed revised Geneva score was designed
with no defeat in diagnostic accuracy and clinical utility
(Table 2)[ 26]. However, the Wells score reported to be more
accurate than simpliﬁed revised version of the Geneva score
for PE assessment [27].
Clinical probability can subsequently be combined with
determination the level of D-dimer, a degradation product
of a crosslinked ﬁbrin blood clot [23]. Although these sys-
tems perform well in predicting pre-test DVT probability
in patients with proximal DVT and outpatients, they are
not as sensitive in hospitalised and patients with isolated
distalDVT[28].Theseinitialstepsallowselectionofpatients
who requires noninvasive imaging techniques [28]s u c ha s
compression ultrasonography and venous ultrasound which
hasreplacedvenographytodiagnoseDVT[24,29].However,
for pelvic vein, venous ultrasound is not as accurate asISRN Hematology 3
Table 2: The main clinical scoring models for predicting the pre-test probability of pulmonary embolism. Well’s score, revised Geneva and
simpliﬁed revised Geneva are scoring systems for assessment of suspected PE [24–26].
Well’s Score Revised and simpliﬁed revised Geneva scores
Clinical characteristics Score Clinical characteristics Revised score Simpliﬁed score
Haemoptysis +1 Age >65 years +1 +1
Cancer +1 Active malignant condition +2 +1
Previous pulmonary embolism or
deep venous thrombosis +1.5 Surgery or fracture within 1 month +2 +1
Haemoptysis +2 +1
Heart rate >100/min +1.5 Previous deep vein thrombosis or
pulmonary embolism
+3 +1
Recent surgery or immobilisation +1.5
Clinical signs of deep venous
thrombosis +3 Unilateral lower-limb pain +3 +1
Heart rate 75–94/min +3 +1
Alternative diagnosis less likely than
that of pulmonary embolism +3
Pain on lower-limp deep venous
palpation and unilateral oedema
+4 +1
Heart rate >94/min +5 +1
Clinical probability Clinical probability
Low <2L o w 0–3 0-1
Intermediate 2–6 Intermediate 4–10 2–4
High >6 High >10 ≥5
lower limb DVT due to a limited acoustic window [29].
Hence, computed tomographic (CT) venography may be
a good alternative for this condition [29]. Pulmonary CT
angiography has also replaced ventilation perfusion scintig-
raphy of the lung or conventional pulmonary angiography
[24, 29]. It has also been reported that combination of this
technique with CT venography provides higher sensitivity
in detection PE [30]. In addition, it has been shown that
transcranial Doppler ultrasonography technique which is
based on detection DVT and high-intensity transient signals
may screen patients for PE after orthopaedic surgery [31].
5. Prevention and Treatment
To prevent thrombus extension, decrease of the risk of
recurrent thrombosis and subsequent death in patient with
VTE pharmacological and/or mechanical approaches can be
administered [8, 32, 33].
5.1. Pharmacological Interventions. The pharmacological
approaches mainly include a wide range of traditional and
new generations of anticoagulants listed in Figure 1.
5.1.1. Conventional Anticoagulants for Treatment of VTE
(1) Unfractionated Heparin (UFH). The initial and stan-
dard pharmacological approach in patient with VTE was
unfractionated heparin (intravenous: i.v.) (UFH) followed
by long-term warfarin [32]. UFH is a heterogenous mixture
of glycosaminoglycans that plays its anticoagulation roles
via binding to antithrombin by a pentasaccharide, catalysing
the inactivation of thrombin and other clotting factors [34].
In addition, UFH has high nonspeciﬁc binding aﬃnities to
endothelial cells, platelet factor 4, and platelets that result
in unpredictable pharmacokinetics and pharmacodynamic
properties [34]. Therefore, UFH required laboratory moni-
toring and has major side eﬀects such as bleeding complica-
tions,immunethrombocytopenia,andosteoporosis[32,34].
(2)Low-Molecular-WeightHeparin(LMWH). UFHhasbeen
replaced with subcutaneous administered low-molecular-
weight heparin (LMWH), for example, enoxaparin, a deriva-
tive of heparin which is polysulfated glycosaminoglycan and
has about one-third the molecular weight of UFH [32, 34,
35]. LMWH is as eﬀective as UFH but safer and can be
administered in a ﬁxed, weight-adjusted dose [32, 34].
(3) Vitamin K Antagonists. Vitamin K antagonists, such
as warfarin, are the most common oral anticoagulants for
prevention and treatment of VTE; However, they have
several disadvantages such as a slow onset of action, a
narrow therapeutic window, food and drug interactions,
and wide interindividual dosing diﬀerences; hence, they are
requited intensive monitoring [36]. Therefore, management
of patients on these chronic oral anticoagulants encounter
diﬃculties, for example, warfarin resistance and the optimal
warfarin initiation dose [36, 37].
5.1.2.NewGenerationofAnticoagulantsforTreatmentofVTE.
To increase the safety and eﬃcacy of anticoagulants that
are more convenient for patients, new generation of oral
anticoagulantshavebeendeveloped[32,35].Theseanticoag-
ulants have been developed from hematophagous organisms
via the application of recombinant DNA technology or
by structure-based drug design [35]. These anticoagulants
target speciﬁc steps in the coagulation cascade such as factor
VIIa/tissue factor, factor Xa, activated protein C and soluble
thrombomodulin, and thrombin [32, 35]. They have been
shown to be eﬀective long-term treatment of VTE in phase



























Figure 1: Diﬀerent pharmaceutical interventions for VTE target various steps in coagulation cascade. Traditional anticoagulants including
unfractionated heparin, low-molecular-weight heparin, and vitamin K antagonists target diﬀerent steps. Despite, new generation of
anticoagulants; rNAPc2 (recombinant nematode anticoagulant protein c2), fondaparinux, rivaroxaban, apixaban, and dabigatran etexilate,
have speciﬁc targets in coagulation pathways.
warfarin [32]. Some of anticoagulants of the new generation
with good potential in treatment of VTE are listed below
(Figure 1).
(1) Nematode Anticoagulant Protein c2 (NAPc2). Nematode
anticoagulant protein c2 (NAPc2) is an inhibitor of factor
VIIa/tissue factor complex pathway. NAPc2 is a natural pro-
tein initially isolated from canine hookworm and has cur-
rently been produced in a recombinant from (rNAPc2) [32,
35]. rNAPc2 forms a complex by binding to a noncatalytic
site on both factors X and/or Xa which directly inhibits
factor VIIa/tissue factor complex [32, 35]. It has been dem-
onstrated the rNAPc2 is as safe and eﬀective as LMWH for
prevention of VTE in patients after elective, unilateral total
knee replacement [32, 36, 38].
(2) Fondaparinux. Fondaparinux indirectly inhibits factor
Xa via binding to AT [32]. Fondaparinux is a synthetic
analogue of the pentasaccharide sequence that binds to AT,
in UFH and LMWH structure, noncovalently and reversibly.
This induces a conformational alteration that enhances the
aﬃnityofATforfactorXaresultingin300-foldincreaseinits
inhibitory eﬀect [32]. The eﬃcacy of fondaparinux depends
on the circulating level of AT, and it cannot be administered
orally [39]. It has been demonstrated that Fondaparinux
administrated once daily subcutaneously (s.c.) is as eﬀective
and safe as adjusted dose of UFH (i.v.) and body weight-
adjusted LMWH (s.c.) in the initial treatment of PE and
DVT, respectively, [40, 41]. Therefore, Fondaparinux can be
a good alternative for LMWH.
(3) Rivaroxaban. Rivaroxaban is an oral direct inhibitor of
factor Xa [39]. Rivaroxaban inhibits factor Xa in a con-
centration-dependent manner via a rapid and reversible
binding [39]. It has been reported that rivaroxaban reduces
the rate of development of VTE in patients after total hip or
knee arthroplastycomparedwithLMWHwithnosigniﬁcant
diﬀerences in risk of bleeding [42–45]. Rivaroxaban has
also shown to reduce costs associated with drug admin-
istration for prophylaxis and treatment of VTE events in
this population as compared with enoxaparin. Rivaroxaban
reduces the incidence of symptomatic VTE as well [46].
Therefore, rivaroxaban may be an answer to unmet need
for replacement of warfarin as well as a good alternative for
LMWH.ISRN Hematology 5
(4) Apixaban. Apixaban is a reversible active direct inhibitor
of factor Xa that can also be administered orally [47]. Pre-
scribing apixaban after knee and hip replacement was more
eﬀective for prevention of VTE as compared with LMWH
without enhancing bleeding risk [48, 49]. In addition ﬁxed-
dose orally administered apixaban may replace LMWH
combined with vitamin K antagonists in treatment of DVT
[47].
(5) Dabigatran Etexilate. Dabigatran etexilate is a competi-
tive reversible oral anticoagulant that inhibits thrombin di-
rectly after conversion to its active form dabigatran. Dabi-
gatran etexilate has the potential to replace traditional anti-
coagulants for prevention of VTE in patients undergone
elective total hip or knee replacement surgery [50, 51].
5.2. Mechanical Approaches. Nonpharmacological interven-
tions, including graduated compression stockings, intermit-
tent pneumatic compression devices, and inferior vena cava
ﬁlters, have the advantage of management of VTE with no
risk of bleeding [52, 53].
5.2.1. Graduated Compression Stockings. Graduated com-
pression stockings apply greater pressure at the ankle than
higher up the leg, therefore, reduce pooling of blood in the
deep veins [52] which can enhance the velocity of blood out-
ﬂow toward the heart [54]. It is recommended that patients
with acute proximal DVT treated with LMWH should walk
withcompressionbandageormedicalcompressionstockings
to assist the recovery from pain and swelling [55]. It has
been reported that below-knee compression elastic stockings
reduces the risk of postthrombotic syndromes by approxi-
mately 50% in patients with proximal DVT [56]. Therefore,
ithasbeenrecommendedthatgraduatedelasticcompression
stockings with pressure of 30–40mmHg at the ankle for
2 years after DVT diagnosis may prevent postthrombotic
syndrome [57]. However, there are controversial reports in
regards to the eﬃciency of graduated compression stocking
on prevention of VTE in patients. Thigh-level stockings are
shownnottobeveryeﬀectiveinpreventingVTE,andbelow-
knee stockings might even enhance thrombosis in patients
with acute stroke [58, 59]. This discrepancy may occur due
to initiation of VTE in patients with diﬀerent diseases. While
thesestockingsmaynotbeaseﬀectiveinpatientswithstroke,
they may be a good approach in other patients. Hence,
future investigation is required to determine the role of these
mechanical methods in prevention of VTE.
5.2.2. Intermitted Pneumatic Compression Devices. Intermit-
ted pneumatic compression devices function by cyclic inﬂa-
tion and deﬂation that promote venous return [52]. While
there are no venographic data available conﬁrming the
eﬃcacy of graduated compression stockings, intermitted
pneumatic compression devices have shown excellent eﬃ-
cacy in several venographic studies over the past 25 years
[54]. Intermitted pneumatic compression devices, including
single chamber, multiple chamber, calf-length, thigh-length,
foot only, and foot and calf, supply air to leg and/or foot
chambers that are intermittently inﬂated with air to a 35
to 55mmHg pressure in a uniform or sequential fashion:
10 to 35 seconds [54]. This follows by 1 minute deﬂation
period to allow the leg or foot to reﬁll with blood [54].
These devices have been used prior to, during and following
surgery to prevent DVT [53]. It has also been reported that
combination of fondaparinux and intermitted pneumatic
compression device was superior to pneumatic compression
alone in reducing the rate of VTE in patients undergoing
abdominal surgery [60].
5.2.3. Inferior Vena Cava Filters. Inferior vena cava ﬁlters
may be inserted through the infrarenal, jugular, femoral, or
antecubital veins to relieve pulmonary vascular obstruction
inpatientswithproximalDVT[53].However,theseﬁltersdo
not prevent VTE in the lower extremities; hence, they should
be combined with pharmacological interventions to reduce
the risk of further development of thrombosis [53].
6. Concluding Remarks
In summary, VTE is a multifactorial disease with both envi-
ronmental and genetic related risk factors. VTE is a signif-
icant threat to individuals that causes various compilations
leading to death as well as ﬁnancial burden for community.
However, this condition can be diagnosed by various non-
invasive cost-eﬀective diagnostic algorithms in combination
with noninvasive imaging techniques. Pharmacological and
nonpharmacological interventions, either alone or in com-
bination, can be used to prevent or manage this condition.
In particular, new generation of anticoagulants to target a
speciﬁc step in coagulation cascade and with the possibility
to replace the common pharmacological treatments due to
enhanced safety and reduced side eﬀects are among the
highlights of current investigations. Meanwhile, the role of
nonpharmacological approaches that are easier to use with
noriskofbleedingshouldnotbeneglected.Thecombination
of both interventions may ease the process of prevention and
treatment of VTE. However, more investigation is required
to fulﬁl these goals.
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